Bioavailability of IgG Administered by the Subcutaneous Route
Open Access
- 1 March 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Clinical Immunology
- Vol. 33 (5), 984-990
- https://doi.org/10.1007/s10875-013-9876-3
Abstract
Purpose US licensing studies of subcutaneous IgG (SCIG) calculate dose adjustments necessary to achieve area under the curve (AUC) of serum IgG vs. time on SCIG that is non-inferior to that on intravenous IgG (IVIG), within the FDA-set limit of ±20 %. The results are interpreted as showing that different SCIGs differ in bioavailability. We used three approaches to determine if the bioavailabilities were actually different. Methods Dose adjustments and AUCs from published licensing studies were used to calculate bioavailabilities using the formula: Bioavailability (% of IVIG) = AUC(SCIG) ÷ AUC(IVIG) x 1/Dose Adjustment. We also compared the increment in serum IgG concentration achieved with varying doses of SCIG in recent meta-analyses with the increment with different doses of IVIG, and determined the serum IgG concentrations when patients switched SCIG products at the same dose. Results The actual bioavailabilities were: Gamunex® 65.0 %, Hizentra® 65.5 %, Gammagard® 67.2 %, Vivaglobin® 69.0 %. Regression analyses of serum IgG vs. dose showed that the mean increase in serum IgG resulting from a 100 mg/kg/month increment in SCIG dosing was 69.4 % of the increase with the same increment in IVIG dosing (84 mg/dL vs. 121 mg/dL). Patients switching SCIG preparations at the same dose had no change in serum IgG levels, confirming that bioavailabilities of the SCIG preparations did not differ. Conclusions Decreased bioavailability appears to be a basic property of SCIG and not a result of any manufacturing process or concentration. Because serum IgG levels do not vary with different SCIG products at the same dose, adjustments are not necessary when switching products.Keywords
This publication has 23 references indexed in Scilit:
- Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapyClinical and Experimental Immunology, 2012
- Subcutaneous Hizentra® (20%) Is Better Tolerated And Shares Similar Efficacy Compared To Subcutaneous Vivaglobin® (16%)Journal of Allergy and Clinical Immunology, 2012
- Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trialArthritis Research & Therapy, 2012
- Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapyClinical Immunology, 2011
- Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary ImmunodeficiencyClinical Pharmacokinetics, 2011
- Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficienciesClinical Immunology, 2011
- Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency diseaseClinical and Experimental Immunology, 2010
- Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 yearsJournal of Allergy and Clinical Immunology, 2010
- Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary ImmunodeficiencyJournal of Clinical Immunology, 2010
- Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous RoutesImmunology and Allergy Clinics of North America, 2008